Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Study Type
3.2. Snippet by Test
3.3. Snippet by Therapeutic Area
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising prevalence of Group B Streptococcus
4.1.1.2. The rising the clinical trials on Group B Streptococcus
4.2. Restraints
4.2.1.1. Extensive testing and documentation can often result in delays
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Study Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
7.1.2. Market Attractiveness Index, By Study Type
7.2. Pharmacodynamics (PD) studies *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Pharmacokinetics (PK) studies
7.4. Toxicology studies
8. By Test
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
8.1.2. Market Attractiveness Index, By Test
8.2. In silico *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. In vitro
8.4. In vivo
9. By Therapeutic Area
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.1.2. Market Attractiveness Index, By Therapeutic Area
9.2. Oncology *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiovascular
9.4. Neurology
9.5. Immunology
9.6. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Pharmaceutical and Biotechnology Companies s*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Contract Research Organizations (CROs)
10.4. Academic and Government Research Institutes
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. UK
11.3.8.3. France
11.3.8.4. Italy
11.3.8.5. Spain
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Labcorp Drug Development *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Charles River Laboratories
13.3. PPD (Pharmaceutical Product Development)
13.4. ICON plc
13.5. Novartis AG
13.6. Merck & Co., Inc.
13.7. AstraZeneca plc
13.8. CMIC HOLDINGS Co., LTD
13.9. ProPharma
13.10. MorphoSys AG
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us